A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Conditions

B-ALL · Leukemia

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Dr Jackie Thomson Inc, Johannesburg, South Africa
Contact: Study coordinator (Jackie Thompson) · Jackie@bonemarrowtransplant.co.za · +27 011 053 1200
Alberts Cellular Therapy, Pretoria, South Africa
Contact: Study coordinator (David Brittain) · david@abj.org.za · +27 012 993 2555

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

B-cell Acute Lymphoblastic Leukemia (B-ALL)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Duarte, United States · Jacksonville, United States

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

B-NHL · B-Non Hodgkin Lymphoma · Acute Lymphocytic Leukemia

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bethesda, United States

KSV01 Injection as the Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

B-ALL

Abroad (travel likely)RecruitingPHASE1

Hangzhou, China

Evaluating the Safety and Efficacy of DuoCAR20.19.22-D95 in Adult Patients With Relapsed or Refractory B-cell Malignancies

B-Cell Non-Hodgkin Lymphoma · B-cell Acute Lymphoblastic Leukemia

Abroad (travel likely)RecruitingPHASE1

Westwood, United States